Stocktwits22d agobullish
BIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home UseThe decision marks a major shift in how patients can begin therapy for early Alzheimer’s disease.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
514last 24h
2493last 7d
477● bullish (7d)
256● bearish (7d)
197publishers
Investing.com23d agobullish
Truist upgrades Biogen to Buy on Alzheimer’s, pipeline optimism ahead of key dataInvesting.com -- Truist Securities upgraded Biogen to Buy from Hold and raised its price target to $235 from $190, citing growing confidence in the company’s Alzheimer’s and immunology pipeline ahead of several major clinical data readouts over the next two years.
Barrons.com23d agobullish
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study DetailsBiogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its experimental Alzheimer’s drug.